Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accounts Payables: 2022-2025

Historic Accounts Payables for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $5.9 million.

  • Stoke Therapeutics' Accounts Payables rose 136.26% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 136.26%. This contributed to the annual value of $2.5 million for FY2024, which is 47.37% up from last year.
  • Stoke Therapeutics' Accounts Payables amounted to $5.9 million in Q3 2025, which was up 36.12% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Accounts Payables ranged from a high of $5.9 million in Q3 2025 and a low of $766,000 during Q4 2022.
  • Moreover, its 3-year median value for Accounts Payables was $2.5 million (2024), whereas its average is $3.1 million.
  • Per our database at Business Quant, Stoke Therapeutics' Accounts Payables tumbled by 56.80% in 2023 and then spiked by 153.53% in 2024.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Accounts Payables stood at $766,000 in 2022, then skyrocketed by 121.28% to $1.7 million in 2023, then spiked by 47.37% to $2.5 million in 2024, then soared by 136.26% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $4.3 million for Q2 2025, and $2.2 million during Q1 2025.